Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.20+0.02 (+0.63%)
Close on Nov 17, 2026Market cap $224.30MP/E –Yield 0.00%
Bicycle Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Bicycle Therapeutics's total assets was $567.18M at Sep 30, 2026. For fiscal 2025 it was $717.60M, down 25.0% from the year before. The highest annual figure on record is $956.87M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $717.60M | -25.0% |
| FY2024 | Dec 31, 2024 | $956.87M | +60.7% |
| FY2023 | Dec 31, 2023 | $595.34M | +45.0% |
| FY2022 | Dec 31, 2022 | $410.61M | -14.4% |
| FY2021 | Dec 31, 2021 | $479.79M | +197.7% |
| FY2020 | Dec 31, 2020 | $161.15M | +46.2% |
| FY2019 | Dec 31, 2019 | $110.19M | +35.0% |
| FY2018 | Dec 31, 2018 | $81.63M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $567.18M | -25.8% |
| Q2 FY2026 | Jun 30, 2026 | $606.58M | -27.1% |
| Q1 FY2026 | Mar 31, 2026 | $652.40M | -26.2% |
| Q4 FY2025 | Dec 31, 2025 | $717.60M | -25.0% |
| Q3 FY2025 | Sep 30, 2025 | $763.95M | -23.4% |
| Q2 FY2025 | Jun 30, 2025 | $832.18M | -21.3% |
| Q1 FY2025 | Mar 31, 2025 | $883.89M | +61.5% |
| Q4 FY2024 | Dec 31, 2024 | $956.87M | +60.7% |
| Q3 FY2024 | Sep 30, 2024 | $996.75M | +56.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.06B | +132.8% |
| Q1 FY2024 | Mar 31, 2024 | $547.14M | +27.6% |
| Q4 FY2023 | Dec 31, 2023 | $595.34M | +45.0% |
| Q3 FY2023 | Sep 30, 2023 | $638.68M | +53.1% |
| Q2 FY2023 | Jun 30, 2023 | $454.17M | +2.0% |
| Q1 FY2023 | Mar 31, 2023 | $428.80M | -6.7% |
| Q4 FY2022 | Dec 31, 2022 | $410.61M | -14.4% |
| Q3 FY2022 | Sep 30, 2022 | $417.15M | +48.3% |
| Q2 FY2022 | Jun 30, 2022 | $445.48M | +97.1% |
| Q1 FY2022 | Mar 31, 2022 | $459.56M | +105.3% |
| Q4 FY2021 | Dec 31, 2021 | $479.79M | +197.7% |
| Q3 FY2021 | Sep 30, 2021 | $281.33M | +65.4% |
| Q2 FY2021 | Jun 30, 2021 | $226.05M | +90.6% |
| Q1 FY2021 | Mar 31, 2021 | $223.84M | +73.1% |
| Q4 FY2020 | Dec 31, 2020 | $161.15M | +46.2% |
| Q3 FY2020 | Sep 30, 2020 | $170.06M | +46.5% |
| Q2 FY2020 | Jun 30, 2020 | $118.60M | -6.1% |
| Q1 FY2020 | Mar 31, 2020 | $129.28M | +58.4% |
| Q4 FY2019 | Dec 31, 2019 | $110.19M | – |
| Q3 FY2019 | Sep 30, 2019 | $116.06M | – |
| Q2 FY2019 | Jun 30, 2019 | $126.25M | – |
| Q4 FY2018 | Dec 31, 2018 | $81.63M | – |
See a number that looks wrong?